Sorry, you need to enable JavaScript to visit this website.
Skip to main content


Sumatriptan Succinate

Sumatriptan Succinate
CAS Number: 103628-48-4

Sumatriptan Succinate

Therapeutic Category
Anti-Migraine
API Technology
Synthetic
Dose From
Nasal
Dr Reddy's Development Status
Available
Available Regulatory Filing
USA
Canada
CEP
Japan
Saudi Arabia
Singapore
Russia
Israel
Innovator Brand (USA)
ZEMBRACE

Mechanism of Action

Sumatriptan binds with high affinity to human cloned 5-HT1B/1D receptors. Sumatriptan presumably exerts its therapeutic effects in the treatment of migraine headache through agonist effects at the 5-HT1B/1D receptors on intracranial blood vessels and sensory nerves of the trigeminal system, which result in cranial vessel constriction and inhibition of pro-inflammatory neuropeptide release.

Indication

ZEMBRACE SymTouch is a serotonin (5-HT1B/1D) receptor agonist (triptan) indicated for:

  • Acute treatment of migraine with or without aura in adults Limitations of Use:
  • Use only if a clear diagnosis of migraine has been established.
  • Not indicated for the prophylactic therapy of migraine.

Dr. Reddy's Expertise

Headquartered in Hyderabad, India, Dr. Reddy's Laboratories is one of the leading Active Pharmaceutical Ingredients (API) suppliers globally. Dr. Reddy's API business is a preferred partner to pharma companies across the US, Europe, Brazil, Latin America, Japan, China, Korea, Middle East and other emerging markets.

Dr. Reddy's API business thrives on the deep technical strengths established over the last 30+ years in the development and manufacture of complex APIs such as steroids, peptides, complex long chain molecules and highly potent APIs (HPAPIs / oncology drugs). This expertise is complemented by our prowess in intellectual property and regulatory affairs which helps us consistently meet and exceed regulatory standards. Dr. Reddy's Sumatriptan Succinate API is the outcome of the extensive expertise in R&D, IP, and Regulatory.

A key component in helping our customers be first to market is a responsive supply chain. We achieve this by making sure that all our facilities are operating efficiently and to the latest standards of quality, safety, and productivity. A strong interconnect between business and factories allows for a quick reaction to dynamic market changes, so that we can avert shortages and meet sudden surges in demand.

Contact Us

Please fill in the following form and we'll get back to you shortly

Email us: api@drreddys.com |   +91 40 49002253

Disclaimer

Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes patent infringement. Availability may be restricted to certain markets or countries. Please Contact Us for more information on availability and product suitability.

All product information, including that with regard to active pharmaceutical ingredients (API), the indication, and possible mechanism(s) of action, is based on publicly available product label.